Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Dividends

Explore dividend yields, payout ratios, and historical trends to maximize your investment strategies.

Last Close
May 28 04:00PM ET
0.1700
Dollar change
-0.0055
Percentage change
-3.13
%
Index- P/E- EPS (ttm)-5.55 Insider Own0.01% Shs Outstand95.54M Perf Week-10.53%
Market Cap16.24M Forward P/E- EPS next Y-0.60 Insider Trans0.00% Shs Float95.54M Perf Month0.89%
Income-98.59M PEG- EPS next Q-0.26 Inst Own15.04% Short Float0.82% Perf Quarter-53.80%
Sales10.25M P/S1.58 EPS this Y-11.05% Inst Trans14.29% Short Ratio0.30 Perf Half Y-65.02%
Book/sh1.47 P/B0.12 EPS next Y37.17% ROA-62.71% Short Interest0.79M Perf Year-90.00%
Cash/sh0.07 P/C2.30 EPS next 5Y- ROE-72.08% 52W Range0.12 - 2.10 Perf YTD-57.82%
Dividend Est.- P/FCF- EPS past 5Y79.31% ROI-85.83% 52W High-91.90% Beta2.18
Dividend TTM- Quick Ratio0.87 Sales past 5Y0.00% Gross Margin-7.12% 52W Low41.43% ATR (14)0.02
Dividend Ex-Date- Current Ratio1.47 EPS Y/Y TTM70.31% Oper. Margin-1032.48% RSI (14)41.69 Volatility11.24% 8.62%
Employees103 Debt/Eq0.09 Sales Y/Y TTM- Profit Margin-961.87% Recom1.00 Target Price2.97
Option/ShortNo / Yes LT Debt/Eq0.06 EPS Q/Q94.33% Payout- Rel Volume0.52 Prev Close0.18
Sales Surprise-35.53% EPS Surprise34.55% Sales Q/Q- EarningsMay 13 AMC Avg Volume2.66M Price0.17
SMA20-6.50% SMA50-17.10% SMA200-62.74% Trades Volume1,452,074 Change-3.13%
Date Action Analyst Rating Change Price Target Change
Apr-18-22Initiated Noble Capital Markets Outperform
Apr-18-19Upgrade ROTH Capital Neutral → Buy $4
Aug-18-17Upgrade ROTH Capital Neutral → Buy $6
Sep-07-16Downgrade ROTH Capital Buy → Neutral
Feb-17-16Reiterated Oppenheimer Outperform $18 → $10
Nov-04-15Initiated Cantor Fitzgerald Buy
Jun-12-15Initiated Oppenheimer Outperform $18
Feb-17-15Reiterated ROTH Capital Buy $10 → $12
Sep-29-14Reiterated ROTH Capital Buy $17 → $10
May-28-24 08:00AM
May-22-24 08:00AM
May-21-24 08:00AM
May-20-24 10:53AM
May-15-24 08:00AM
04:30PM Loading…
May-13-24 04:30PM
Apr-29-24 09:00AM
Apr-24-24 08:00AM
Apr-09-24 06:31AM
Apr-01-24 04:15PM
Mar-28-24 09:32AM
Mar-25-24 08:00AM
Mar-24-24 04:05PM
Mar-21-24 08:00AM
Mar-20-24 08:00AM
08:00AM Loading…
Mar-19-24 08:00AM
Mar-12-24 08:00AM
Mar-11-24 08:00AM
Mar-07-24 09:37AM
08:00AM
Mar-06-24 08:00AM
Mar-05-24 08:00AM
Feb-29-24 08:00AM
Feb-28-24 08:00AM
06:56AM
06:54AM
Feb-27-24 08:00AM
Feb-26-24 08:00AM
Feb-25-24 02:12PM
Feb-23-24 09:30AM
08:00AM Loading…
Feb-20-24 08:00AM
Feb-16-24 09:30AM
Feb-15-24 08:45AM
08:00AM
Feb-14-24 08:00AM
Feb-13-24 08:00AM
Feb-12-24 08:00AM
Feb-01-24 08:00AM
Jan-31-24 07:00AM
Jan-30-24 05:00PM
Jan-29-24 07:00AM
Jan-26-24 05:31PM
Jan-25-24 07:00AM
Jan-24-24 03:28PM
Jan-09-24 07:00AM
Jan-03-24 07:00AM
Jan-02-24 06:08AM
Dec-20-23 10:35AM
10:30AM
Dec-14-23 09:15AM
Dec-12-23 01:40PM
Dec-11-23 07:00AM
Dec-04-23 07:00AM
Nov-28-23 07:00AM
Nov-20-23 01:57PM
01:53PM
Nov-15-23 07:00AM
Nov-13-23 07:00AM
Nov-09-23 04:15PM
Nov-02-23 08:00AM
Oct-31-23 05:00PM
Oct-30-23 07:00AM
Oct-26-23 07:00AM
Oct-25-23 08:45AM
Oct-19-23 07:00AM
Oct-18-23 07:00AM
Oct-16-23 07:00AM
Oct-12-23 07:00AM
Oct-11-23 07:00AM
Oct-09-23 07:00AM
Oct-04-23 07:00AM
Sep-28-23 09:00PM
04:01PM
Sep-27-23 08:30AM
Sep-26-23 10:18AM
Sep-21-23 07:00AM
Sep-19-23 01:54PM
Sep-18-23 07:00AM
Sep-15-23 09:30AM
Sep-14-23 07:00AM
Sep-06-23 07:00AM
Sep-05-23 07:32AM
07:05AM
07:00AM
Aug-28-23 01:13PM
Aug-21-23 01:18PM
07:00AM
Aug-17-23 07:00AM
Aug-16-23 07:00AM
Aug-10-23 04:30PM
Aug-07-23 07:00AM
Aug-01-23 04:01PM
07:00AM
Jul-31-23 07:00AM
Jul-27-23 09:31PM
04:01PM
Jul-26-23 04:05PM
Jul-24-23 07:00AM
Jul-17-23 07:00AM
Jul-10-23 07:00AM
Tonix Pharmaceuticals Holding Corp. is a clinical-stage biopharmaceutical company, which focuses on the discovery, acquisition, and development of small molecules and biologics to treat and prevent human disease and alleviate suffering. Its portfolio includes TNX-102 SL, TNX-601, TNX-801, and TNX-1800. The company was founded by Seth Lederman and Donald W. Landry on November 16, 2007 and is headquartered in Chatham, NJ.